SYK

Stryker Corporation (SYK) | Rumor.io

Stryker

SYK

Attention (50-day avg)0.03%

Attention rank (50-day avg)#230

Bullish sentiment (50-day avg)50%

Price to earnings ratio28.3

Market capitalization105.6B

Earnings per share9.64

Dividend yield (TTM)1.28%

Revenue (annual)25.1B

Net income (annual)3.2B

Social

What share of all stock conversation is about SYK?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.01% +0.01	0% -0.01	0.04% +0.03	0.01% 0

Sep 19

Stryker Corporation (SYK) is a diversified medical technology company with a strong track record of innovation and revenue growth, with a trailing P/E ratio of 28.54x and a forward P/E ratio of 16.47x.
The company's revenue growth has been driven by its ability to innovate and expand its product offerings, but some analysts are concerned about the impact of declining reimbursement rates and hospitals' increasing price consciousness on the company's margins.
Stryker's financial performance has been robust, with a trailing ROE of 16.51% and a forward ROE of 15.80%, but the company's CFO has indicated that the slowdown in revenue growth will continue into Q4, mainly due to macroeconomic issues.

Generated by AI

Sentiment

Of the messages about SYK that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	80.25% -11.49	50.47% +1.45	79.82% -7.83
Bearish	0%	19.75% +11.49	49.53% -1.45	20.18% +7.83

Bullish· Mar 12

$SYK is poised for more medtech momentum with 11% revenue growth, catching investors' eyes.
Stryker Corporation's recent performance is suggesting that the current story is only part of the whole picture, with potential for small-cap names to reprice fast.
$SYK bought the dip at $329 and is experiencing an impressive come-back, with some considering it an easy money opportunity.

Bearish· Mar 12

Stryker Corporation's operations have been disrupted by a cyberattack related to the Iranian conflict, including order processing, manufacturing, and shipping.
The cyberattack has resulted in a significant data breach, with 200,000+ devices wiped clean, and may lead to HIPAA lawsuits and potential financial losses.
The company's stock price has fallen 3.6% after confirming the cyberattack, and analysts are reaffirming bearish price targets, with some predicting a significant drop to $12.80.

Generated by AI

Topics

Of the messages about SYK that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	50%	16.67%	0.09%	4.59%
Analysts	0%	0%	49.13%	41.65%
Technical Analysis	50%	66.67%	10.13%	6.32%
Macro	0%	0%	39.69%	38.57%
Earnings	0%	16.67%	0.96%	7.25%
Controversies	0%	0%	0%	1.62%

Earnings· Jan 29

Stryker Corporation's Q4 2025 earnings beat estimates with adjusted EPS of $4.47 and revenue of $7.17B, up 11.4% YoY.
The company reported a 56% jump in reported EPS and 11.0% organic growth in Q4, finishing 2025 with an acceleration in revenue.
Stryker expects 2026 organic net sales growth of 8.0-9.5% and adjusted net earnings per diluted share of $14.90-$15.10, with a modestly favorable pricing impact.

Analysts· May 2

Stifel Nicolaus raised Stryker's price target to $330, while Barclays, Wells Fargo, Baird, BTIG, Piper Sandler, Jefferies, and JP Morgan Chase raised their targets to $321, $336, $315, $313, $310, $345, and $315, respectively.
Morgan Stanley and Deutsche Bank maintained their "Equal-Weight" and "Hold" ratings on Stryker, but raised their price targets to $295 and $292, respectively.
Analysts have raised their numbers on Stryker, with a 75% buy consensus among 35 analysts, and the company has raised its FY outlook, but shares still dropped.

Announcements· Mar 12

Stryker Corporation's (SYK) operations have been disrupted by a cyberattack linked to the Iranian conflict, affecting order processing, manufacturing, and shipping.
The cyberattack has caused delays in order processing and manufacturing, and has impacted the company's ability to accept new orders for equipment and implants.
Stryker has stated that the timeline for a full restoration of its systems is not yet known, and that its electronic ordering system is currently down.

Macro· Jun 15

Stryker shares jumped 4% after UnitedHealth's remarks on increased medical procedures.
UnitedHealth CEO said older adults on Medicare are accessing services more frequently, driving up medical costs.
Health insurance stocks, including UnitedHealth, slid after warning of increased costs due to more surgeries.

Technical Analysis· May 16

The stock $SYK has reached a new high, with a +0.01% increase, and is approaching its next resistance level of 65.05.
This resistance level is significant, as it is a price level that $SYK has not reached since March 9, 2011.
The +0.01% increase suggests a minor but steady upward trend in the stock, potentially indicating a continued rise towards its next resistance level.

Generated by AI

Community

Of the messages about SYK, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	42.99%	44.74%	72.75%	47.09%
Newcomers	57.01%	55.26%	27.25%	52.91%

Regulars· Jul 31

Stryker Corporation's Q2 FY26 earnings report showed revenue of $6.6B, a 9.4% year-over-year increase, and adjusted EPS of $3.69, a 17.9% YoY increase.
The company's organic net sales growth was 9.0% and its adjusted operating margin was 27.4%, a 170 basis point year-over-year increase.
Stryker's FY26 guidance calls for organic growth of 8.3-9.3%.

Newcomers· Sep 19

The newcomer comments on Stryker's ability to innovate and its diversified product offerings, citing personal experience and industry knowledge.
Some newcomers consider Stryker a good buy, but express concerns about the company's ability to weather a slowdown in hospital purchasing due to price-consciousness and reimbursement trends.
The newcomer who would buy SYK at current levels suggests that the company's financial performance and valuation support a positive outlook for the stock, citing analysis of key financial ratios and metrics.

Generated by AI

Stryker's sales have grown about 10% a year on average over the past three years, and so have ResMed's. That shared growth rate in medical devices is the bet the two have in common. Stryker (SYK) is the giant, selling hospitals everything from hip and knee products to capital equipment. ResMed is a sleep device maker with less than a quarter of Stryker's revenue. Stryker costs 32.6 times its past year's earnings, against 21.9 times for ResMed. So does Stryker's reach justify that higher price? T

1d agoYahoo Finance

What Does General Dynamics (GD) Winning New Stryker Work Mean Through 2028?

General Dynamics (NYSE:GD) received a new multi year U.S. Army contract modification for Double V Hull A1 Stryker vehicles, extending through 2028. The award enlarges the Army Stryker program backlog and adds funded production for upgraded armored vehicles across multiple brigade combat teams. The contract update supports continued manufacturing at General Dynamics Land Systems facilities that produce Stryker chassis and mission packages. The extra Double V Hull A1 Stryker work is...

6d agoYahoo Finance

Can Stryker Vehicle Demand Support General Dynamics' Growth?

Detailed price information for General Dynamics Corp (GD-N) from The Globe and Mail including charting and trades.

6d agoThe Globe and Mail

Here's Why You Should Hold Stryker Stock in Your Portfolio for Now

SYK's resilient demand, Mako robotics growth and margin gains support its outlook despite cyber and supply disruptions.

6d agoYahoo Finance

Minimally Invasive Robotic Surgical System Market Global Report 2026: Benchmark Intuitive Surgical, Johnson & Johnson, Medtronic, Stryker and Zimmer Biomet Now

Players: Intuitive Surgical, Johnson & Johnson, Medtronic, Stryker, Zimmer Biomet. Profile covers competitors, segments, regional shares, trends and opportunities. Minimally Invasive Robotic Surgical System Market Minimally Invasive Robotic Surgical System Market Dublin, Sept. 23, 2026 (GLOBE NEWSWIRE) -- "Minimally Invasive Robotic Surgical System Market Global Report 2026" has been added to ResearchAndMarkets.com's offering. Minimally Invasive Robotic Surgical System Market to Reach $18.15 Bil

7d agoYahoo Finance UK

Also Discussed

Investors talking about SYK also mention

#	Name	Attention
1	Zimmer Biomet Holdings, Inc.ZBH	0%0
2	Medtronic plcMDT	0%+0
3	Boston Scientific Corp.BSX	0.03%-0.02
4	Intuitive Surgical Inc.ISRG	0%0
5	Smith & Nephew plc Sponsored ADRSNN	0%new
6	Danaher Corp.DHR	0.02%+0.02
7	Becton, Dickinson and CompanyBDX	0%0
8	Edwards Lifesciences CorporationEW	0%new
9	ABMD - Abiomed, Inc.	——
10	Johnson & JohnsonJNJ	0%-0.06

Stryker Corporation

Healthcare
Medical Devices

Stryker Corporation is a medical technology company that develops and markets products used in hospitals, surgery centers, and other healthcare settings. Its current portfolio spans MedSurg, Neurotechnology, and Orthopaedics, with offerings that include surgical equipment, endoscopy systems, patient handling and emergency care devices, neurosurgical and neurovascular products, spinal devices, and implants for joint replacement and trauma procedures. The company also provides technologies and equipment designed to support clinicians in performing procedures more efficiently and to improve patient care across a wide range of specialties. Stryker Corporation serves healthcare professionals and institutions worldwide, making it a significant supplier in the global medical devices market. Founded in 1946 and headquartered in Portage, Michigan, Stryker remains focused on medical technologies that are widely used in surgical, orthopedic, and neuro specialty care.

Website

Location

1941 Stryker Way

Portage, MI, 49002

United States

Social

What share of all stock conversation is about SYK?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.01% +0.01	0% -0.01	0.04% +0.03	0.01% 0

Sep 19

Stryker Corporation (SYK) is a diversified medical technology company with a strong track record of innovation and revenue growth, with a trailing P/E ratio of 28.54x and a forward P/E ratio of 16.47x.
The company's revenue growth has been driven by its ability to innovate and expand its product offerings, but some analysts are concerned about the impact of declining reimbursement rates and hospitals' increasing price consciousness on the company's margins.
Stryker's financial performance has been robust, with a trailing ROE of 16.51% and a forward ROE of 15.80%, but the company's CFO has indicated that the slowdown in revenue growth will continue into Q4, mainly due to macroeconomic issues.

Generated by AI

Sentiment

Of the messages about SYK that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	80.25% -11.49	50.47% +1.45	79.82% -7.83
Bearish	0%	19.75% +11.49	49.53% -1.45	20.18% +7.83

Bullish· Mar 12

$SYK is poised for more medtech momentum with 11% revenue growth, catching investors' eyes.
Stryker Corporation's recent performance is suggesting that the current story is only part of the whole picture, with potential for small-cap names to reprice fast.
$SYK bought the dip at $329 and is experiencing an impressive come-back, with some considering it an easy money opportunity.

Bearish· Mar 12

Stryker Corporation's operations have been disrupted by a cyberattack related to the Iranian conflict, including order processing, manufacturing, and shipping.
The cyberattack has resulted in a significant data breach, with 200,000+ devices wiped clean, and may lead to HIPAA lawsuits and potential financial losses.
The company's stock price has fallen 3.6% after confirming the cyberattack, and analysts are reaffirming bearish price targets, with some predicting a significant drop to $12.80.

Generated by AI

Topics

Of the messages about SYK that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	50%	16.67%	0.09%	4.59%
Analysts	0%	0%	49.13%	41.65%
Technical Analysis	50%	66.67%	10.13%	6.32%
Macro	0%	0%	39.69%	38.57%
Earnings	0%	16.67%	0.96%	7.25%
Controversies	0%	0%	0%	1.62%

Earnings· Jan 29

Stryker Corporation's Q4 2025 earnings beat estimates with adjusted EPS of $4.47 and revenue of $7.17B, up 11.4% YoY.
The company reported a 56% jump in reported EPS and 11.0% organic growth in Q4, finishing 2025 with an acceleration in revenue.
Stryker expects 2026 organic net sales growth of 8.0-9.5% and adjusted net earnings per diluted share of $14.90-$15.10, with a modestly favorable pricing impact.

Analysts· May 2

Stifel Nicolaus raised Stryker's price target to $330, while Barclays, Wells Fargo, Baird, BTIG, Piper Sandler, Jefferies, and JP Morgan Chase raised their targets to $321, $336, $315, $313, $310, $345, and $315, respectively.
Morgan Stanley and Deutsche Bank maintained their "Equal-Weight" and "Hold" ratings on Stryker, but raised their price targets to $295 and $292, respectively.
Analysts have raised their numbers on Stryker, with a 75% buy consensus among 35 analysts, and the company has raised its FY outlook, but shares still dropped.

Announcements· Mar 12

Stryker Corporation's (SYK) operations have been disrupted by a cyberattack linked to the Iranian conflict, affecting order processing, manufacturing, and shipping.
The cyberattack has caused delays in order processing and manufacturing, and has impacted the company's ability to accept new orders for equipment and implants.
Stryker has stated that the timeline for a full restoration of its systems is not yet known, and that its electronic ordering system is currently down.

Macro· Jun 15

Stryker shares jumped 4% after UnitedHealth's remarks on increased medical procedures.
UnitedHealth CEO said older adults on Medicare are accessing services more frequently, driving up medical costs.
Health insurance stocks, including UnitedHealth, slid after warning of increased costs due to more surgeries.

Technical Analysis· May 16

The stock $SYK has reached a new high, with a +0.01% increase, and is approaching its next resistance level of 65.05.
This resistance level is significant, as it is a price level that $SYK has not reached since March 9, 2011.
The +0.01% increase suggests a minor but steady upward trend in the stock, potentially indicating a continued rise towards its next resistance level.

Generated by AI

Community

Of the messages about SYK, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	42.99%	44.74%	72.75%	47.09%
Newcomers	57.01%	55.26%	27.25%	52.91%

Regulars· Jul 31

Stryker Corporation's Q2 FY26 earnings report showed revenue of $6.6B, a 9.4% year-over-year increase, and adjusted EPS of $3.69, a 17.9% YoY increase.
The company's organic net sales growth was 9.0% and its adjusted operating margin was 27.4%, a 170 basis point year-over-year increase.
Stryker's FY26 guidance calls for organic growth of 8.3-9.3%.

Newcomers· Sep 19

The newcomer comments on Stryker's ability to innovate and its diversified product offerings, citing personal experience and industry knowledge.
Some newcomers consider Stryker a good buy, but express concerns about the company's ability to weather a slowdown in hospital purchasing due to price-consciousness and reimbursement trends.
The newcomer who would buy SYK at current levels suggests that the company's financial performance and valuation support a positive outlook for the stock, citing analysis of key financial ratios and metrics.

Generated by AI

Stryker

Social

Sep 19

Bullish· Mar 12

Bearish· Mar 12

Earnings· Jan 29

Analysts· May 2

Announcements· Mar 12

Macro· Jun 15

Technical Analysis· May 16

Regulars· Jul 31

Newcomers· Sep 19

Stifel cuts Stryker stock price target on revenue pressures

Is ResMed A Better Way Than Stryker To Own Medical Device Growth?

What Does General Dynamics (GD) Winning New Stryker Work Mean Through 2028?

Can Stryker Vehicle Demand Support General Dynamics' Growth?

Here's Why You Should Hold Stryker Stock in Your Portfolio for Now

Minimally Invasive Robotic Surgical System Market Global Report 2026: Benchmark Intuitive Surgical, Johnson & Johnson, Medtronic, Stryker and Zimmer Biomet Now

Also Discussed

Stryker Corporation

Company Information

Location

Stifel cuts Stryker stock price target on revenue pressures

Is ResMed A Better Way Than Stryker To Own Medical Device Growth?

What Does General Dynamics (GD) Winning New Stryker Work Mean Through 2028?

Can Stryker Vehicle Demand Support General Dynamics' Growth?

Here's Why You Should Hold Stryker Stock in Your Portfolio for Now

Minimally Invasive Robotic Surgical System Market Global Report 2026: Benchmark Intuitive Surgical, Johnson & Johnson, Medtronic, Stryker and Zimmer Biomet Now

Also Discussed

Social

Sep 19

Bullish· Mar 12

Bearish· Mar 12

Earnings· Jan 29

Analysts· May 2

Announcements· Mar 12

Macro· Jun 15

Technical Analysis· May 16

Regulars· Jul 31

Newcomers· Sep 19